Puma Biotechnology Prices $180M Stock Offering
Ticker: PBYI · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $107,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: stock-offering, capital-raise, equity
TL;DR
Puma Biotech prices $180M stock offering at $45/share.
AI Summary
On August 14, 2024, Puma Biotechnology, Inc. announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price of $45.00 per share. The company expects to receive gross proceeds of approximately $180 million before deducting underwriting discounts and commissions and other offering expenses.
Why It Matters
This capital raise could fund future research and development or acquisitions, potentially impacting the company's growth trajectory and stock value.
Risk Assessment
Risk Level: medium — Public offerings can dilute existing shareholders and signal a need for capital, which may indicate financial pressures or aggressive growth plans.
Key Numbers
- $180M — Gross Proceeds (From the public offering of common stock.)
- 4,000,000 — Shares Offered (Common stock to be sold in the public offering.)
- $45.00 — Price Per Share (The price at which the common stock is being offered.)
Key Players & Entities
- Puma Biotechnology, Inc. (company) — Registrant
- August 14, 2024 (date) — Date of earliest event reported
- 4,000,000 (dollar_amount) — Number of shares offered
- $45.00 (dollar_amount) — Price per share
- $180 million (dollar_amount) — Expected gross proceeds
FAQ
What is the purpose of this public offering?
The filing does not explicitly state the purpose of the offering, but it is a common way for companies to raise capital for operations, research, or expansion.
When was the offering priced?
The offering was priced on August 14, 2024.
How many shares are being offered?
The company is offering 4,000,000 shares of its common stock.
What is the price per share?
The shares are being offered at a price of $45.00 per share.
What are the expected gross proceeds from this offering?
The company expects to receive gross proceeds of approximately $180 million before deducting expenses.
Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 11.2 · Accepted 2024-08-15 09:00:10
Key Financial Figures
- $0.0001 — on which registered Common Stock , $0.0001 par value per share PBYI The Nasdaq
- $107,500,000 — ugh December 31, 2023, in the amount of $107,500,000. A separate bench trial related to cert
Filing Documents
- pbyi20240815_8k.htm (8-K) — 32KB
- 0001437749-24-026953.txt ( ) — 166KB
- pbyi-20240814.xsd (EX-101.SCH) — 3KB
- pbyi-20240814_def.xml (EX-101.DEF) — 12KB
- pbyi-20240814_lab.xml (EX-101.LAB) — 15KB
- pbyi-20240814_pre.xml (EX-101.PRE) — 12KB
- pbyi20240815_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On September 22, 2021, the Company filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 ("the '314 patent") and 10,596,162 ("the '162 patent") (Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al., 1:21CV01338 (D. Del. Sep. 22, 2021)). The Company's complaint alleges that AstraZeneca's commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the '314 and '162 patents. The Company is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement. Wyeth is a co-plaintiff. Plaintiffs seek a judgment that AstraZeneca's product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. The parties stipulated to dismiss AstraZeneca PLC as a defendant and Pfizer as a Counterclaim Defendant on December 10, 2021, which the Court so ordered on December 13, 2021. The Company filed its answer to AstraZeneca's counterclaims on December 17, 2021, denying those claims. The case was reassigned to visiting Judge Matthew Kennelly of the Northern District of Illinois. A Markman Hearing was conducted on March 17, 2023, and the Court issued its claim construction decision on March 29, 2023. Fact discovery closed on May 19, 2023, and expert discovery closed on November 17, 2023. The Court denied the parties' respective motions for summary judgment and Daubert motions, other than to clarify that Plaintiffs' damages cannot extend to any time period before the asserted patents were issued. The Court gra
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 15, 2024 PUMA BIOTECHNOLOGY, INC. a Delaware Corporation By: /s/ Alan Auerbach Name: Alan H. Auerbach Title: Chief Executive Officer, President and Chairman of the Board